(C) Common Dreams
This story was originally published by Common Dreams and is unaltered.
. . . . . . . . . .
A bill is reintroduced in Congress to revise provisions in drug-pricing law [1]
['Ed Silverman', 'A Senior Writer', 'Pharmalot Columnist At Stat', 'Has Been Covering The Pharmaceutical Industry For Nearly Three Decades.', 'Pharmalot Columnist', 'Senior Writer', 'Stat Staff', 'Megan Molteni', 'Adam Feuerstein', 'Lizzy Lawrence']
Date: 2025-02-25
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades.
Once again, House lawmakers have introduced a bill to alter a key provision of the Inflation Reduction Act in response to arguments that the federal law is discouraging investment in developing so-called small molecule medicines.
The legislation, known as the Ensuring Pathways to Innovative Cures Act, would allow Medicare to begin negotiating with pharmaceutical companies over the prices of small molecule medicines 13 years after they reach the market. Currently, negotiations begin after nine years and the legislation — which was re-introduced by Rep. Greg Murphy (R-N.C.) — would shift the timetable so that it is the same as for large molecule medicines, also known as biologics.
advertisement
By making this change, the legislation would remove what the pharmaceutical industry and its investors claim is a disincentive for pursuing small molecule drugs, since these medicines would have less time on the market before Medicare would be able to negotiate set prices. This process means there will be small returns on investments for small molecule drugs, according to those who support the bill.
[END]
---
[1] Url:
https://www.statnews.com/pharmalot/2025/02/25/medicare-pills-biologics-pharmaceuticals-medicine/
Published and (C) by Common Dreams
Content appears here under this condition or license: Creative Commons CC BY-NC-ND 3.0..
via Magical.Fish Gopher News Feeds:
gopher://magical.fish/1/feeds/news/commondreams/
